High-Dose antifungal drug tested against deadly zygomycosis
NCT ID NCT00467883
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tested a high dose (10 mg/kg/day) of the antifungal drug liposomal amphotericin B (Ambisome) in 40 people with zygomycosis, a rare but serious fungal infection. The goal was to see if the high dose could effectively control the infection after 4 weeks of treatment. Researchers measured complete or partial response to treatment, as well as safety and survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- liposomal amphotericin B (Ambisome)
- What this could lead to
- If successful, this could provide a more effective treatment option for zygomycosis, a serious fungal infection.
- What could go wrong
- This is a small Phase 2 trial with only 40 participants, so results may not apply broadly. High doses of Ambisome can cause kidney problems and other side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ZYGOMYCOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Necker - Service des Maladies Infectieuses et Tropicales
Paris, 75015, France
-
Necker Hospital
Paris, 75015, France